Physiomics (PYC) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Feb 2015 07:00 AM
RNS
Termination of Equity Swap Agreement
15 Dec 2014 01:08 PM
RNS
Result of AGM
12 Nov 2014 10:24 AM
RNS
Final Results
04 Nov 2014 07:00 AM
RNS
Disclosure of Large Pharma partner Merck & Co
27 Oct 2014 10:07 AM
RNS
Project extension with global pharma company
13 Oct 2014 04:43 PM
RNS
Holding(s) in Company
07 Oct 2014 09:35 AM
RNS
Cardiotox Platform Launch
29 Aug 2014 02:47 PM
RNS
Holding(s) in Company
14 Aug 2014 01:10 PM
RNS
New deal with global pharma
24 Jul 2014 12:59 PM
RNS
Issue of Equity
26 Jun 2014 07:57 AM
RNS
Holding(s) in Company
12 Jun 2014 07:00 AM
RNS
Anticipated new collaboration with Diatech
20 May 2014 09:47 AM
RNS
Holding(s) in Company
10 Apr 2014 07:00 AM
RNS
Second validation of Virtual Tumour Clinical
03 Apr 2014 07:00 AM
RNS
Virtual Tumour Clinical Validation
14 Feb 2014 07:00 AM
RNS
Half Yearly Report
30 Jan 2014 04:41 PM
RNS
Issue of Equity - Replacement
30 Jan 2014 03:02 PM
RNS
Issue of Equity
16 Jan 2014 07:20 AM
RNS
Dundee University Collaboration
17 Dec 2013 02:07 PM
RNS
Result of AGM
04 Dec 2013 10:47 AM
RNS
Virtual Tumour Proposal
28 Nov 2013 01:24 PM
RNS
DrugCARD launch
15 Nov 2013 07:00 AM
RNS
Final Results
11 Nov 2013 07:00 AM
RNS
University of Oxford Collaboration
04 Nov 2013 07:00 AM
RNS
Update on the Virtual Tumour Clinical platform
10 Oct 2013 10:30 AM
RNS
Drawdown pursuant to SEDA Arrngmnt/Issue of Equity
07 Oct 2013 08:32 AM
RNS
Physiomics gains new speciality pharma customer
01 Oct 2013 11:49 AM
RNS
Physiomics gains first large pharma customer
16 Sep 2013 07:00 AM
RNS
Physiomics to present cardiac toxicity platform
26 Jul 2013 01:30 PM
RNS
Issue of Equity
01 Jul 2013 07:00 AM
RNS
Additional SEDA Drawdown
24 Jun 2013 07:00 AM
RNS
Wins Poster Award
20 Jun 2013 04:28 PM
RNS
Award of Grant
11 Jun 2013 07:00 AM
RNS
Population Approach Group Europe
06 Jun 2013 07:00 AM
RNS
Virtual Tumour Clinical Contract
08 Apr 2013 08:03 AM
RNS
Physiomics to present new developments
25 Mar 2013 07:00 AM
RNS
Physiomics to provide cardiac toxicity modelling
18 Mar 2013 07:00 AM
RNS
New clinical PK/PD modelling service
13 Feb 2013 11:10 AM
RNS
Issue of Options
11 Feb 2013 03:23 PM
RNS
Director Declaration
08 Feb 2013 07:00 AM
RNS
Half Yearly Report
22 Jan 2013 07:00 AM
RNS
SEDA Arrangement
07 Jan 2013 07:00 AM
RNS
Recruitment of Senior Scientist with Clinical PK/P
18 Dec 2012 09:46 AM
RNS
French R&D Tax Credit Accreditation
17 Dec 2012 12:29 PM
RNS
Result of AGM
14 Nov 2012 07:00 AM
RNS
Final Results for the year ended 30 June 2012
08 Oct 2012 08:38 AM
RNS
New US Business Development Consultant
10 Aug 2012 07:53 AM
RNS
New Agreement to optimise oncology combination
07 Aug 2012 03:57 PM
RNS
Stmnt re Share Price Movement
04 Jul 2012 03:25 PM
RNS
Trading Update

Physiomics plc is a UK-based company that uses mathematical models to help develop cancer treatments and personalized medicine. Services include Virtual Tumor modeling: A combination of proprietary and industry standard technologies that predict the effects of cancer treatments and drugs, Answering R&D questions: Helping clients de-risk drug development and build confidence in a molecule's clinical potential and Predicting therapeutic windows: Helping clients achieve a more quantitative understanding of new molecules.

PYC share price listed at 231p in 2004.

UK 100

Latest directors dealings